FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial. PMID 42070197 · Dermatol Ther (Heidelb) · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Mapping the mRS Into the EQ-5D-5L in Patients With Ischemic Stroke. PMID 42052683 · Stroke · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial. PMID 42044642 · Lancet Neurol · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Virtual health coaching to improve self-care among informal caregivers of hospitalized older adults during a transition in care: Randomized controlled trial study protocol. PMID 42031229 · Contemp Clin Trials · 2026-Jun 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Comparison of KN012, a denosumab biosimilar, versus reference denosumab in Chinese postmenopausal women with osteoporosis: efficacy, safety, and population pharmacokinetics in a 12-month phase III study. PMID 42006557 · Bone Rep · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis. PMID 41997804 · Ann Rheum Dis · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| An integrated restricted mean survival time-based evaluation of efficacy, toxicity, and cost in first-line immunotherapy regimens for metastatic renal cell carcinoma. PMID 41991383 · Urol Oncol · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France. PMID 41973335 · Drugs Real World Outcomes · 2026-Jun The record describes a real-world descriptive analysis of an early access program for olaparib combination therapy in prostate cancer. While it mentions the PROpel Phase III trial as the basis for approval, it does not report the results of that trial. The study itself is non-randomized, does not present time-to-event efficacy endpoints, and is not an original report of a randomized trial result. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated versus conventional IMRT in unfavorable intermediate- and high-risk prostate cancer: A phase II comparative study of PSA kinetics, dosimetric and toxicity outcomes. PMID 41967586 · Fr J Urol · 2026-Jun The record describes a Phase II randomized trial, not a Phase III or IIIb trial as required. Although it meets other criteria (oncology, human, randomized, time-to-event endpoint, drug intervention), the phase is insufficient for eligibility. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in indian adults with obesity: A phase III randomized non-inferiority trial. PMID 41953358 · Metabol Open · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemotherapy for obstructive colon cancer derived by a stoma: Study protocol of the FRENCH-01 randomized phase III trial (COnCERTO Trial). PMID 41945039 · Dig Liver Dis · 2026-Jun 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Aficamten: First Approval. PMID 41941083 · Drugs · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Protocol summary and statistical analysis plan for the bone loss prevention with zoledronic acid or denosumab in critically ill adults (BONE ZONE) trial. PMID 41940313 · Crit Care Resusc · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis. PMID 41936548 · Obesity (Silver Spring) · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The role of circulating tumor DNA in precision adjuvant therapy for colorectal cancer: a scoping review. PMID 41935608 · J Gastrointest Surg · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee. PMID 41934464 · J Thorac Oncol · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach. PMID 41906858 · Diabetes Obes Metab · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| KORT - Knee osteoarthrosis radiotherapy trial: Protocol for a multidisciplinary pathway and a planned sham-controlled phase III trial of low-dose radiotherapy in knee osteoarthritis. PMID 41859527 · Osteoarthr Cartil Open · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Host-directed therapy for tuberculosis: Repurposed drugs toward global tuberculosis elimination. PMID 41856464 · Int J Infect Dis · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Clinical and metabolic benefits of efruxifermin in MASH: a GRADE-assessed meta-analysis of randomized trials with trial sequential analysis. PMID 41843368 · Hepatol Int · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial. PMID 41840328 · Rheumatol Ther · 2026-Jun 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. PMID 41840238 · Nat Med · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 2 Figure · 8 Panel · risk visible |
| Immunotherapy failure in glioblastoma: A systematic review and meta-analysis of randomized controlled trials. PMID 41839399 · Crit Rev Oncol Hematol · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Once-weekly insulin GZR4 versus once-daily insulin degludec in Chinese people with type 2 diabetes: A multicenter, open-label, randomized, phase 2 trial. PMID 41833659 · Metabolism · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study. PMID 41817930 · Ann Surg Oncol · 2026-Jun The trial is a Phase 3, randomized, placebo-controlled oncology trial with a drug intervention. However, based on the provided metadata (title indicates it's about surgical outcomes after neoadjuvant treatment), the primary or key secondary endpoint appears to be a pathological/surgical outcome (e.g., pathological complete response), not a time-to-event endpoint like OS, PFS, or DFS. Therefore, it fails the 'time_to_event' criterion. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study. PMID 41814037 · Rheumatol Ther · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307. PMID 41811656 · Oncol Ther · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 3 Figure · 6 Panel · risk visible |
| Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-A. PMID 41779098 · Neurol Ther · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Expanding the conversation around radiotherapy for lentigo maligna: Response to "Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial". PMID 41740890 · J Am Acad Dermatol · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial. PMID 41713476 · Lancet Infect Dis · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Surrogate Endpoints for Overall Survival in Advanced Hepatocelluar Carcinoma in the Era of Immunotherapy: A Trial Level Meta-Analysis. PMID 41694651 · Liver Cancer · 2026-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2221-34. PMID 41644375 · Eur Urol · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal and gastric peritoneal metastases: Where are we today? PMID 41547607 · J Visc Surg · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. PMID 41454190 · Ann Surg Oncol · 2026-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 4 Figure · 12 Panel · risk visible |
| A methodological review of pragmatic designs in acute stroke trials. PMID 41347705 · Int J Stroke · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents. PMID 40763320 · JCO Oncol Pract · 2026-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Oral Levosimendan for the Treatment of Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction: Rationale and Design of the LEVEL Trial. PMID 40633684 · J Card Fail · 2026-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Multicenter randomized effectiveness/implementation trial of a digital self-management support tool to improve the quality of life during adjuvant hormonal therapy for patients with early breast cancer: The HOPE trial. PMID 42501860 · Contemp Clin Trials · 2026-Jul-25 The record describes a Phase-unspecified randomized trial protocol (no results) with a drug intervention (adjuvant endocrine therapy) and a primary quality-of-life endpoint. It does not report original formal results for a time-to-event efficacy endpoint as required. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prioritizing Chemotherapy in Total Neoadjuvant Therapy Improves pCR Rate in Locally Advanced Rectal Cancer in Countries with Limited Radiotherapy Access: A Randomized Controlled Trial. PMID 42501213 · J Gastrointest Cancer · 2026-Jul-25 The record describes a randomized trial in oncology with a drug intervention and a time-to-event secondary endpoint (OS), but the phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata. Furthermore, the primary efficacy endpoint is pathological complete response (pCR), which is not a time-to-event endpoint. While OS is a time-to-event endpoint, it is reported as an exploratory secondary outcome with immature results. Therefore, the trial does not meet the eligibility criteria for a definitive randomized trial with a primary/key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| On Hierarchical Composite Endpoints in Pediatric Cancer Supportive Care: Illustrative Examples From Two Multi-Center Phase-III Randomized Clinical Trials. PMID 42499270 · Pediatr Blood Cancer · 2026-Jul-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial. PMID 42498834 · Leukemia · 2026-Jul-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
H
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Blood-based cell-free DNA for addressing colorectal cancer screening disparities: a study protocol for a randomised trial. PMID 42498482 · BMJ Open · 2026-Jul-24 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. PMID 42497381 · J Clin Oncol · 2026-Jul-24 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study. PMID 42496861 · Adv Ther · 2026-Jul-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
H
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy. PMID 42496653 · Oncologist · 2026-Jul-24 This is a Phase III, randomized, drug-intervention trial in advanced breast cancer, but it reports on visual safety and patient-reported outcomes, not a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it does not meet the inclusion criteria for a time-to-event efficacy report. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal. PMID 42483956 · Expert Rev Anticancer Ther · 2026-Jul-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol 2026;89:437-45. PMID 42493340 · Eur Urol · 2026-Jul-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings on Multiparametric MRI (PRIMARY2): A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Trial. Lancet Oncol 2026;27:839-848. PMID 42493339 · Eur Urol · 2026-Jul-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial. PMID 42493213 · J Immunother Cancer · 2026-Jul-23 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
H
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Exploring the Feasibility, Acceptability, and Safety of a 4:3 Intermittent Fasting Weight Loss Program Among Stage I-III Breast Cancer Survivors With Overweight or Obesity: Protocol for a 6-Month Proof-of-Concept Feasibility Trial. PMID 42492498 · JMIR Res Protoc · 2026-Jul-23 This is a protocol for a proof-of-concept feasibility trial investigating a behavioral weight-loss intervention (intermittent fasting and exercise) among breast cancer survivors. It is not a randomized Phase III trial, does not involve a drug intervention, and does not report time-to-event efficacy outcomes. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |